U.S. Markets close in 3 hrs 1 mins

FluoroPharma Medical, Inc. (FPMI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.025-0.003 (-10.714%)
As of 12:17PM EDT. Market open.
People also watch

FluoroPharma Medical, Inc.

8 Hillside Avenue
Suite 108
Montclair, NJ 07042
United States

Full Time Employees4

Key Executives

Dr. Thomas H. Tulip Ph.D.Chief Exec. Officer, Pres and Director320kN/A64
Ms. Tamara RheinChief Financial Officer130kN/A45
Mr. Edward L. Lyons Jr.VP of Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Corporate Governance

FluoroPharma Medical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.